Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Current Value
$46.901 Year Return
Current Value
$46.901 Year Return
Market Cap
$1.79B
P/E Ratio
-12.29
1Y Stock Return
166.88%
1Y Revenue Growth
801.96%
Dividend Yield
0.00%
Price to Book
7.5
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BSM | 0.04% | $3.17B | -13.01% | 10.65% |
SIGI | -0.04% | $5.90B | -4.96% | 1.47% |
PSLV | 0.08% | - | - | 0.00% |
GFI | 0.09% | $13.42B | +10.06% | 2.63% |
SDRL | 0.10% | $2.74B | -4.48% | 0.00% |
UNM | 0.11% | $13.16B | +69.20% | 2.16% |
AQN | 0.12% | $3.79B | -20.96% | 8.21% |
SD | -0.17% | $430.19M | -10.98% | 3.79% |
ACDC | 0.19% | $1.08B | -17.28% | 0.00% |
CI | 0.21% | $89.70B | +12.57% | 1.68% |
XASAX | 0.22% | - | - | 0.20% |
KMI | -0.22% | $62.38B | +64.02% | 4.07% |
CNQ | 0.25% | $71.04B | +1.89% | 6.81% |
VZ | -0.26% | $176.51B | +12.56% | 6.37% |
MKL | 0.31% | $21.48B | +16.38% | 0.00% |
DGX | 0.31% | $17.99B | +19.98% | 1.84% |
NOMD | -0.32% | $2.74B | +4.53% | 2.67% |
MOS | 0.32% | $8.07B | -29.32% | 3.28% |
AMRK | -0.37% | $697.61M | +7.29% | 2.67% |
OHI | 0.37% | $10.84B | +26.02% | 6.71% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ADMA | 36.43% | $4.88B | +423.60% | 0.00% |
ALEC | 36.00% | $377.04M | -19.46% | 0.00% |
VKTX | 35.24% | $5.74B | +353.83% | 0.00% |
PLRX | 34.33% | $778.32M | -9.55% | 0.00% |
FYBR | 33.13% | $8.65B | +66.27% | 0.00% |
WRLD | 31.92% | $667.35M | +5.26% | 0.00% |
HSII | 31.70% | $914.74M | +64.66% | 1.35% |
IRTC | 31.58% | $2.36B | -9.35% | 0.00% |
XHR | 31.53% | $1.51B | +19.71% | 3.13% |
ALDX | 30.97% | $294.18M | +102.46% | 0.00% |
RXST | 30.94% | $1.82B | +62.89% | 0.00% |
SANA | 30.33% | $526.91M | -41.15% | 0.00% |
RCUS | 29.48% | $1.33B | +5.07% | 0.00% |
CDLX | 29.36% | $178.39M | -54.00% | 0.00% |
DOCS | 29.26% | $9.62B | +114.35% | 0.00% |
CDXS | 29.21% | $345.86M | +121.35% | 0.00% |
TVTX | 29.20% | $1.51B | +207.79% | 0.00% |
MATW | 29.17% | $731.28M | -31.68% | 4.06% |
GLDD | 29.08% | $828.12M | +90.26% | 0.00% |
BLFS | 29.04% | $1.04B | +64.64% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HUSA | -16.19% | $16.69M | -11.56% | 0.00% |
COR | -16.02% | $47.48B | +21.20% | 0.86% |
PGR | -15.77% | $149.10B | +57.29% | 0.45% |
MCK | -15.51% | $78.15B | +35.51% | 0.42% |
STG | -15.36% | $35.67M | +7.92% | 0.00% |
LMT | -14.89% | $126.40B | +18.99% | 2.36% |
USM | -14.50% | $5.35B | +41.82% | 0.00% |
ACGL | -13.65% | $36.00B | +16.84% | 0.00% |
RNR | -13.44% | $13.74B | +23.09% | 0.58% |
BMY | -12.82% | $118.10B | +20.11% | 4.09% |
NOC | -12.70% | $71.54B | +4.23% | 1.60% |
FATBB | -12.55% | $81.94M | -12.91% | 11.69% |
PG | -11.95% | $402.15B | +14.14% | 2.33% |
CL | -11.88% | $76.48B | +22.25% | 2.12% |
NERV | -11.83% | $14.69M | -58.00% | 0.00% |
GIS | -11.77% | $34.85B | -2.91% | 3.78% |
TMUS | -11.71% | $270.63B | +56.92% | 0.83% |
CB | -11.41% | $114.43B | +26.00% | 1.24% |
CNC | -11.38% | $29.19B | -21.56% | 0.00% |
RYAN | -11.34% | $8.81B | +55.63% | 0.62% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -29.59% | $388.04M | 1.43% |
VIXY | -22.58% | $195.31M | 0.85% |
TAIL | -18.39% | $67.98M | 0.59% |
USDU | -9.14% | $201.97M | 0.5% |
TBLL | -8.69% | $1.92B | 0.08% |
IYK | -7.58% | $1.30B | 0.4% |
XBIL | -7.20% | $637.70M | 0.15% |
UUP | -6.94% | $309.25M | 0.77% |
IBDP | -6.79% | $2.11B | 0.1% |
TPMN | -6.75% | $40.60M | 0.65% |
EQLS | -6.71% | $76.08M | 1% |
IBD | -6.63% | $330.68M | 0.44% |
USCI | -6.49% | $185.47M | 1.07% |
FTSM | -6.30% | $6.08B | 0.45% |
DBE | -6.24% | $50.13M | 0.77% |
HIGH | -6.00% | $302.78M | 0.51% |
TOTL | -5.96% | $3.31B | 0.55% |
CSHI | -5.94% | $482.85M | 0.38% |
BUXX | -5.81% | $162.67M | 0.25% |
CTA | -5.61% | $350.27M | 0.78% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBA | 0.37% | $755.88M | 0.93% |
RING | -0.37% | $716.67M | 0.39% |
FLRN | 0.53% | $2.33B | 0.15% |
CANE | 0.53% | $17.72M | 0.29% |
ULST | 0.57% | $535.47M | 0.2% |
MLPX | -0.66% | $2.21B | 0.45% |
JUCY | 0.68% | $324.29M | 0.6% |
XLP | 0.82% | $16.03B | 0.09% |
AGGH | -0.87% | $253.02M | 0.33% |
XHLF | -0.91% | $874.27M | 0.03% |
TBIL | -1.04% | $4.38B | 0.15% |
LTPZ | 1.09% | $715.65M | 0.2% |
YEAR | -1.12% | $1.13B | 0.25% |
MLPA | 1.25% | $1.64B | 0.45% |
RSPG | -1.31% | $544.63M | 0.4% |
SHV | 1.33% | $18.13B | 0.15% |
IBDQ | 1.34% | $2.89B | 0.1% |
KRBN | 1.35% | $242.47M | 0.85% |
SPLV | 1.36% | $8.93B | 0.25% |
IXC | -1.49% | $2.20B | 0.41% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PTH | 43.90% | $143.31M | 0.6% |
XBI | 40.42% | $6.58B | 0.35% |
XPH | 35.74% | $157.87M | 0.35% |
IWC | 34.53% | $933.99M | 0.6% |
ARKG | 33.90% | $1.13B | 0.75% |
IWO | 33.75% | $12.56B | 0.24% |
GNOM | 33.49% | $70.59M | 0.5% |
PEJ | 32.17% | $257.98M | 0.57% |
FV | 31.89% | $3.81B | 0.9% |
ITEQ | 31.48% | $84.84M | 0.75% |
RZV | 31.28% | $258.76M | 0.35% |
EIS | 30.97% | $163.73M | 0.59% |
ISCG | 30.91% | $640.00M | 0.06% |
IJT | 30.85% | $6.64B | 0.18% |
EES | 30.81% | $668.71M | 0.38% |
FXD | 30.77% | $1.54B | 0.61% |
IBB | 30.60% | $6.66B | 0.45% |
VIOO | 30.58% | $3.12B | 0.1% |
SPSM | 30.57% | $12.72B | 0.03% |
PFUT | 30.47% | $326.69M | 0.64% |
Yahoo
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo
Tarsus Pharmaceuticals ( NASDAQ:TARS ) Third Quarter 2024 Results Key Financial Results Revenue: US$48.1m (up by...
Yahoo
Tarsus Pharmaceuticals Inc (TARS) reports its most successful quarter with $48 million in net sales, expanded coverage, and a growing sales force.
Yahoo
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
SeekingAlpha
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsDavid Nakasone - Head, IRBobby...
Yahoo
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across objective measures of Meibomian Gland Disease and important patient sympt